Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Jim Mac who wrote (155)	11/4/1997 4:04:00 AM
From: Jim Mac	Read Replies (2) \| Respond to of 4140

According to "BEYOND GLASSES" by Franette Armstrong, it appears HH (hyperopic holmium) treatments may have only limited effectiveness. Beyond +1.5 to +1.75 diopters of hyperopia, it appears excimer lasers will be the only effective treatment, at least for a while. By the time SNRS gets FDA approval to sell in U.S., maybe in late 1999, or in 2000, VISX, Summit, Autonomous, Nidek, and other excimer laser manufacturers will have U.S. approval to do most degrees of hyperopia, along with myopia and astigmatism. So, don't get too carried away with the promise of big money. That's what people did with VISX and Summit years ago, and then reality struck. But Nanny made some good points about the price advantages, and cost containment threat posed by managed care. I hope SNRS can perfect their tech for higher levels of hyperopia. I also hope LASIK dies, as soon as "no-touch" PRK is available in U.S., maybe in a few years.